Abivax SA (ABVX) - Total Liabilities
Based on the latest financial reports, Abivax SA (ABVX) has total liabilities worth €117.55 Million EUR (≈ $137.43 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore ABVX strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Abivax SA - Total Liabilities Trend (2013–2025)
This chart illustrates how Abivax SA's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see total assets of Abivax SA.
Abivax SA Competitors by Total Liabilities
The table below lists competitors of Abivax SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Westlake Chemical Corporation
NYSE:WLK
|
USA | $10.23 Billion |
|
SpareBank 1 Sør-Norge ASA
OL:SB1NO
|
Norway | Nkr491.18 Billion |
|
Henan Shenhuo Coal & Power Co Ltd
SHE:000933
|
China | CN¥23.64 Billion |
|
Suzhou Everbright Photonics Co. Ltd. A
SHG:688048
|
China | CN¥320.36 Million |
|
Campbell’s Co
NYSE:CPB
|
USA | $10.99 Billion |
|
Gildan Activewear Inc.
TO:GIL
|
Canada | CA$7.07 Billion |
|
Skyworks Solutions Inc
NASDAQ:SWKS
|
USA | $2.13 Billion |
|
Brenntag SE
F:BNR
|
Germany | €7.20 Billion |
Liability Composition Analysis (2013–2025)
This chart breaks down Abivax SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See net asset quality index of Abivax SA to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.25 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.27 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Abivax SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Abivax SA (2013–2025)
The table below shows the annual total liabilities of Abivax SA from 2013 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €129.14 Million ≈ $150.97 Million |
-21.57% |
| 2024-12-31 | €164.64 Million ≈ $192.49 Million |
+25.63% |
| 2023-12-31 | €131.05 Million ≈ $153.21 Million |
+83.37% |
| 2022-12-31 | €71.47 Million ≈ $83.56 Million |
-12.40% |
| 2021-12-31 | €81.59 Million ≈ $95.39 Million |
+22.46% |
| 2020-12-31 | €66.62 Million ≈ $77.89 Million |
+66.78% |
| 2019-12-31 | €39.95 Million ≈ $46.70 Million |
+105.98% |
| 2018-12-31 | €19.39 Million ≈ $22.67 Million |
+244.17% |
| 2017-12-31 | €5.63 Million ≈ $6.59 Million |
+45.23% |
| 2016-12-31 | €3.88 Million ≈ $4.54 Million |
-14.35% |
| 2015-12-31 | €4.53 Million ≈ $5.30 Million |
+12.38% |
| 2014-12-31 | €4.03 Million ≈ $4.71 Million |
-9.29% |
| 2013-12-31 | €4.44 Million ≈ $5.20 Million |
-- |
About Abivax SA
ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials f… Read more